Sartorius Stedim has invested about Rs 28.52 crore in India for expanding
its competencies and capabilities
Sartorius Stedim India
Amit Chatterjee (CEO)
Life Sciences Business
Laboratory and process technology provider
No.10, 3rd Phase, Peenya 6th Main, KIADB Industrial Area, Bangalore-560 058, Karnataka
(in Rs Crore)
Rs 95 Crore
Sartorius offers the widest and best integrated portfolio in the
industry for manufacturing pharmaceuticals using single-use and hybrid systems
The Sartorius Group is an internationally-leading laboratory and process technology provider
covering biotechnology and mechatronics segments.
The company reported sales of Rs 95 crore from its life sciences business in FY09 as against
Rs 90 crore in FY08.
Though the downturn affected Sartorius, the company still went ahead with its ambitious growth
plans and investments in making India the center of excellence for its Asian market requirements.
About Rs 28.52 crore (€5 mn) has been invested in India for expanding the competencies, capability
and capacity to serve the group and Asian market requirements. Since the beginning of this year,
the company has seen large orders for core equipments for large biopharmaceutical plants.
In production technology, the biopharmaceutical industry is currently witnessing a complete paradigm
shift. The industry is increasingly switching from stainless steel equipment to single-use products.
As a market-focused organization, Sartorius has been strategically heading and propelling developments
to create a portfolio of products and services to serve its customers with a total solutions approach.
While the equipment business slowed down in line with the economic sentiments, the consumable and
single-use devices saw a significant growth. The industry really promoted the membrane-based
chromatography devices which saw it move from R&D through process development into commercial
production in several customers in vaccine industry. The trend towards single-use fluid handling
bags, connectors and more critically, the bioreactors, was quite evident as the industry looked
to reduce its capital costs and speed up its expansion and development time.
With the best-in-class design, engineering, manufacturing, process control and application support
competencies in India, the company offers the widest and best integrated portfolio in the industry
for the manufacture of pharmaceuticals using single-use and hybrid systems. The company is
optimistic that it would be launching highly attractive new products for the biopharmaceutical
industry and R&D in 2010 as well.